Skip to main content Accessibility help
×
Home

Considering depression as a consequence of activation of the inflammatory response system

  • J. Korf (a1), H. C. Klein (a1), J. Versijpt (a1) (a2), J. A. den Boer (a1) and G. J. ter Horst (a1)...

Abstract

This paper summarizes the possible interrelation between peripheral and/or cerebral inflammation and depression. Often, depression is regarded as a consequence of life events, including disabling diseases. The question addressed here is whether activation of the inflammatory response system (IRS) can cause depression. Epidemiological studies suggest that depression can be precipitated by bacterial or viral infections. In depressed patients, peripheral markers of the IRS are often increased. There is some evidence that some forms of depression are caused by a viral infection of the limbic system. More consistent are the observations that depression in diseases with active cerebral inflammatory processes (e.g. multiple sclerosis, Alzheimer's disease) may concur. Direct evidence of a relation between depression and inflammation was found in post-mortem brain material of patients with a vascular depression. In both inflammatory brain diseases and in depression, a state-dependent increased hypothalamus–pituitary–adrenal axis activity is seen. Animals studies have shown that intact cerebral serotonin systems are required for the activation of the IRS following an endotoxin challenge and that long-term treatment with antidepressants may change such a response. Gender differences between the prevalence of depression and inflammatory diseases are similar, as more females are affected. We hypothesize that cerebral or peripheral activation of the IRS may contribute to the course of some antidepressant treatment-resistant depressions. Clinical trials combining antidepressants and drugs that reduce the activation of the IRS may provide evidence for such proposed depression subtypes.

Copyright

Corresponding author

Department Psychiatry, P6.11, PO Box 30.001, NL 9700 RB Groningen, the Netherlands. Tel: 00 31 50 3612100; Fax: 00 31 50 3611699; E-mail: j.korf@acggn.azg.nl

References

Hide All
1.Selye, H. A syndrome produced by diverse nocuous agents. Nature 1936;138:3233.
2.Pacak, K, Palkovits, M, Yadid, G, Kvetnansky, R, Kopin, IJ, Goldstein, DS. Heterogeneous neurochemical responses to different stressors. a test of Selye's doctrine of non-specificity. Am J Physiol 1998;275:R1247R1255.
3.Sapolsky, RM, Romero, LM, Munck, AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:5589.
4.Dorian, B, Garfinkel, PE. Stress, immunity and illness − a review. Psychol Med 1987;17:393407.
5.Anisman, H, Zalcman, S, Zacharko, RM. The impact of stressors on immune and central neurotransmitter activity: bidirectional communication. Rev Neurosci 1993;4:147180.
6.Yirmiya, R. Behavioural and psychological effects of immune activation: implications for ‘depression due to a general medical condition’. Curr Trends Psychiatry 1997;10:470476.
7.Kronfol, Z, Remick, DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683694.
8.Licino, J, Wong, M-L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999;4:317327.
9.Rivest, S, Lacroix, S, Vallieres, L, Nadeau, S, Zhang, J, Laflamme, N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000;223:2238.
10.Van der Werf, YD, De Jongste, MJL, Ter Horst, GJ. The immune system mediated blood brain barrier damage. possible implications for pathology of neuropsychiatric illnesses. Acta Neuropsychiatr 1995;7:114121.
11.Maes, M, Song, C, Lin, Aet al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998;10:313318.
12.Maes, M. Psychological stress, cytokines and the inflammatory response system. Curr Opin Psychiatry 1999;19:695700.
13.Dugue, B, Leppanen, EA, Teppo, AM, Fyhrquist, F, Grasbeck, R. Effects of psychological stress on plasma interleukins-1β and 6, C-reactive protein, tumour necrosis factor α, antidiuretic hormone and serum cortisol. Scand J Clin Lab Invest 1993;555561.
14.Maes, M, Goossens, F, Lin, A, De Meester, I, Van Gatel, A, Scharpe, S. Effects of psychological stress on serum prolyl endopeptidase and dipeptyl peptidase IV activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety. Psychoendoneuroendocrinology 1998;23:485495.
15.Maes, M. Evidence for an immune response in major depression. a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1138.
16.Maes, M, Meltser, HY, Scharpe, Set al. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression. Psychiatr Res 1993;49:151165.
17.Frommberger, UH, Baurer, J, Haselbauer, P, Fraulin, A, Riemann, D, Berger, M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatr Clin Neurosci 1997;247:228233.
18.Seidel, A, Arolt, V, Hunstiger, M, Rink, L, Behnisch, A, Kirchner, H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 1996;78:8385.
19.Thomas, AJ, Ferrier, IN, Kalaria, RNet al. Elevation in late life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 2000;157:16821684.
20.Zorilla, EP, McKay, JR, Luborsky, L, Schmidt, K. Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry 1996;153:626635.
21.Fisher, CM. Hypomanic symptoms caused by herpes simplex encephalitis. Neurology 1997;47:13741378.
22.Caparros-Lefebvre, D, Girard-Buttaz, I, Reboul, Set al. Cognitive and psychiatric impairment in herpes simplex virus encephalitis suggest involvement of amygdalo-frontal pathways. J Neurol 1996;243:248256.
23.Sheline, YI, Wang, PW, Gado, MH, Csernansky, JG. Hippocampus atrophy in recurrent depression. Proc Natl Acad Sci USA 1996;93:39083913.
24.Sapolsky, RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925935.
25.Corey, L, Spear, RG. Infections with herpes simplex viruses. N Engl J Med 1981;314:749757.
26.Ferzst, R, Severus, E, Bode, L, Brehm, M, Kuhl, KP, Ludwig, H. Activated Borna disease virus in affective disorders. Pharmacopsychiatry 1999;32:9396.
27.Dietrich, DE, Bode, L, Spannhuth, CWet al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Dis 2000;2:6570.
28.Amsterdam, JDD, Maislin, G, Potter, L, Giuntoli, R. Reduced rate of recurrent genital herpes infections with Lithium carbonate. Psychopharmacol Bull 1990;26:343347.
29.Amsterdam, JD, Maislin, G, Rybakowski, J. A possible anti-viral action of lithium carbonate in herpes simplex virus infections. Biol Psychiatry 1990;27:447453.
30.Meijer, A, Zakay-Rones, Z, Morag, A. Post-influenzal psychiatric disorder in adolescents. Acta Psychiatr Scand 1988;78:176181.
31.Maj, M. Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection. Br J Psychiatry 1996;168:117122.
32.Holden, RJ, Pakula, IS, Mooney, PA. An immunological model connecting the pathogenesis of stress, depression and carcinoma. Med Hypoth 1998;51:309314.
33.MacKenzie, CR, Gonzalez, RG, Kniep, E, Och, S, Daubener, W. Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv Exp Med 1999;567:533539.
34.Appels, A, Baer, FW, Baer, J, Bruggeman, C, De Beats, M. Inflammation, depressive symptomatology, and corony artery disease. Psychosom Med 2000;62:601605.
35.Berger, AK, Fratiglioni, L, Forsell, Y, Windblad, B, Backman, L. The occurrence of depressive symptoms in the preclinical phase of AD. Neurology 1999;53:19982002.
36.McGeer, PL, McGeer, EG. Inflammation of the brain in Alzheimer's disease: implications for therapy. J Neurosci News 1998;1:2935.
37.Weissman, MM, Klerman, GL. Gender and depression. Trends Neurosci 1985;8:416420.
38.Generini, MM, Cutolo, M, Kottinen, Y, et al. Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol 1988;10:220235.
39.Kessler, RC, McGonagle, KA, Schwartz, M, Blazer, D G, Nelson, CB. Sex and depression in the national comorbidity survey. I. Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:8596.
40.Fassbinder, K, Schmidt, R, Moβner et al. Mood disorders and dysfunction of the hypothalamic–pituitary–adrenal axis in multiple sclerosis. Association with cerebral inflammation. Arch Neurol 1998;55:6672.
41.Sadovnick, AD, Remick, RA, Allen, Jet al. Depression and multiple sclerosis. Neurology 1996;46:628632.
42.Hatzinger, M. Neuropeptides and the hypothalamic–pituitary–adrenocortical (HPA) system: review of recent research strategies in depression. World J Biol Psychiatry 2000;1:105111.
43.Dieperink, E, Willenbring, M, Ho, SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000;157:867876.
44.Van Gool, AR, Kruit, WHJ, Cornelissen, JJ, Berk, L, Eggermont, AMM, Bannink, M. Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatry 1999;11:120124.
45.Dunn, AJ, Wang, J, Ando, T. Effects of cytokines on cerebral neurotransmission: comparison with the effects of stress. Adv Exp Med 1999;461:117127.
46.Alberati-Giani, D, Cesura, AM. Expression of the kynurenine enzymes in macrophages and microglia cells: regulation by immune modulators. Amino-Acids 1998;14:251255.
47.Moreno, FA, Gelenberg, AJ, Heninger, GRet al. Tryptophan depletion and depressive vulnerability. Biol Psychiatry 1999;46:498505.
48.Rogers, J, Kirby, LC, Hempelman, SRet al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:16091611.
49.Wyss-Coray, T, Mucke, L. Ibuprofen, inflammation and Alzheimer's disease. Nature Med 2000;6:973974.
50.Weidenfeld, J, Yirmiya, R. Effects of bacterial endotoxine on the glucocorticoid feedback regulation of adrenocortical response to stress. Neuroimmunomodulation 1966;3:352357.
51.Ribeiro, SCM, Tandon, R, Grunhaus, L, Greden, JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:16181629.
52.Thase, ME, Dube, S, Bowler, Ket al. Hypothalamic–pituitary–adrenocortical activity and response to cognitive behaviour therapy in unmedicated hospitalized depressed patients. Am J Psychiatrry 1996;153:886891 .
53.Debattista, CC, Posener, JA, Kalehzan, BM, Schatzberg, AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind. placebo-controlled study. Am J Psychiatry 2000;157:13341337.
54.Tops, M, Van Der Pompe, G, Baas, Det al. Acute cortisol effects on immediate free recall and recognition of nouns in young volunteers depend on affective content of the stimuli. Psychophysiology 2000.
55.Lupien, SJ, McEwen, BS. The acute effects of corticosteroids on cognition: integration of animal and human studies. Brain Res Rev 1997;24:124.
56.Heim, C, Ehlert, U, Hellhammer, DH. The potential role of hypocorticolism in the pathophysiology of stress related bodily disorders. Psychoendocrinology 2000;25:113.
57.Rothwell, NJ, Hopkins, SJ. Cytokines and the nervous system. Trends Neurosci 1995;18:130136.
58.Patterson, PH, Nawa, H. Neuronal differentiation factors/cytokines and synaptic plasticity. Cell 1993;10:123137.
59.Yirmiya, R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996;711:163174.
60.Song, C. The interaction between cytokines and neurotransmitters in depression and stress: possible mechanism of antidepressant treatments. Human Psychopharm Clin Exp 2000;15:199211.
61.Versijpt, J, Decco, D, Dumont, Fet al. SPECT − imaging of inflammation in senile dementia of the Alzheimer type: a pilot study[Abstract]. Neurobiol Aging 2000;21 (Suppl. 252):1151.
62.Banati, RB, Myers, R, Goerres, G, Kreutzberg, GW, Brooks, DJ. [11C]PK11195 PET-imaging of microglial activation in multiple sclerosis[Abstract]. Neurology 1997;48:A313.
63.Graham, YP, Heim, C, Goodman, SH, Miller, AH, Nemeroff, CB. The effects of neonatal stress on brain development: implications for psychopathology. Dev Psychopathol 1999;11:545565.
64.Heim, C, Nemeroff, CB. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry 1999;46:15091522.
65.Lopez, JF, Akil, H, Watson, J. Role of biological and psychological factors in early development and their impact on adult life: neural circuits mediating stress. Biol Psychiatry 1999;46:14611471.
66.Modell, S, Lauer, CJ, Schreiber, W, Huber, ZJ, Krieg, J-C, Holsboer, F. Hormonal response pattern in the combined Dex-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychoparmacology 1998;18:253262.
67.Holsboer, F, Lauer, CJ, Schreiber, W, Krieg, J-C. Altered hypothalamic–pituitary–adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;65:340347.
68.Francis, D, Diorio, J, Liu, D, Meanay, MJ. Nongenomic transmission across generations of maternal behaviour and stress response in the rat. Science 1999;286:11551158.DOI: 10.1126/science.286.5442.1155
69.Francis, DD, Meaney, MJ. Maternal care and the development of stress response. Curr Opin Neurobiol 1999;9:128134.
70.Liu, D, Diorio, J, Day, JC, Francis, DD, Meaney, MJ. Maternal care, hippocampus and cognitive development in rats. Nature Neurosci 2000;3:799806.
71.Shanks, N, Taroque, S, Meaney, MJ. Neonatal endotoxin exposure alters the development of the hypothalamic-pituitary-adrenal axis: early illness and later responsivity to stress. J Neurosci 1995;15:376384.
72.Ruda, MA, Ling, Q-D, Hohmann, AG, Peng, YB, Tachibana, T. Altered nociceptive neuronal circuits after neonatal peripheral inflammation. Science 2000;289:628630.
73.Fox, DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumour necrosis factor. Arch Intern Med 2000;160:437444.
74.Infante, R, Lahita, RG. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs. Geriatrics 2000;55:3040.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed